Should antiviral treatment be extended to patients with chronic hepatitis B and mildly elevated alanine aminotransferase?

Hepatology

Volumn 51, Issue 4, 2010, Pages 1107-1109

  Lok, Anna S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B(E) ANTIGEN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; CHRONIC HEPATITIS; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; EDITORIAL; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER;

EID: 77950609492     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23496     Document Type: Editorial

References (13)

1. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Ann Intern Med 2009;150:104-110.
2. DegertekinB, Lok AS. Indications for therapy in hepatitis B. HEPATOLOGY 2009;49:S129-S137.
3. Lok AS, McMahon BJ. Practice guidelines: chronic hepatitis B. HEPATOL-OGY 2007;45:507-539.
4. Lok AS, McMahon BJ. AASLD practice guidelines: chronic hepatitis B 2009. http://www.aasld.org/practiceguidelines/.
5. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263-283.
6. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.
7. Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, Sharma BC, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008;134:1376-1384.
8. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007;47:760-767.
9. Tsang PS, Trinh H, Garcia RT, Phan JT, Ha NB, Nguyen H, et al. Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels. Clin Gastroenterol Hepatol 2008;6:569-574.
10. AndreaniT,Serfaty L, MohandD, Dernaika S, Wendum D, Chazouilleres O, et al. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol 2007;5:636-641.
11. Hui CK, Leung N, Yuen ST, Zhang HY, Leung KW, Lu L, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. HEPATOLOGY 2007;46:395-401. (Pubitemid 47344774)
12. Wu IC, Lai CL, Han SH, Han KH, Gordon SC, Chao YC, et al. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. HEPATOLOGY 2010;51:1185-1189.
13. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. HEPATOLOGY 2002;36:186-194.